The beneficial role of thiamine in parkinson disease

CNS Neuroscience and Therapeutics

Volumn 19, Issue 7, 2013, Pages 461-468

  Luong, Khanh V Q ^a   Nguyễn, Lan T H ^a  

^a Vietnamese American Medical Research Foundation   (United States)

Author keywords

Parkinson disease; Thiamine; Transketolase

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CASPASE 3; CYTOCHROME C; DOPAMINE TRANSPORTER; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THIAMINE; TRANSCRIPTION FACTOR SP1; TYROSINE 3 MONOOXYGENASE; VASCULOTROPIN;

BRUSH BORDER; DOPAMINE RELEASE; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; INTESTINE ABSORPTION; PARKINSON DISEASE; PATHOLOGY; REVIEW;

ANIMALS; HUMANS; PARKINSON DISEASE; SIGNAL TRANSDUCTION; THIAMINE; VITAMINS;

EID: 84879023640     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12078     Document Type: Review

References (143)

1. Tadano T, Abe Y, Morikawa Y, et al. Involvement of dopaminergic neurons in mouse-killing aggression in rats. Methods Find Exp Clin Pharmacol 1997;19:527-531.
2. Onodera K. Effects of decarboxylase inhibitors on muricidal suppression by L-dopa in thiamine deficient rats. Arch Int Pharmacodyn Ther 1987;285:263-276.
3. Jiménez-Jimnénez FJ, Molina JA, Hernánz A, et al. Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease. Neurosci Lett 1999;271:33-36.
4. Sjöquist B, Johnson HA, Neri A, Lindén S. The influence of thiamine deficiency and ethanol on rat brain catecholamines. Drug Alcohol Depend 1988;22:167-193.
5. Mousseau DD, Raghsvendra Rao VL, Butterworth RF. Vesicular dysfuction during experimental thiamine deficiency is indicated by alterations in dopamine metabolism. Eur J Pharmacol 1996;317:263-267.
6. Yamashita H, Zhang Y-X, Nakamura S. The effects of thiamine and its phosphate esters on dopamine release in the rat striatum. Neurosci Lett 1993;158:229-231.
7. Baker H, Frank O, Chen T, Feingold S, DeAngelis B, Baker E. Vitamin content of some normal human brain segments. J Neurosci Res 1984;11:419-435.
8. Laforenza U, Patrini C, Poloni M, et al. Thiamine- mono- and pyrophosphatase activities from brain homogenate of Guamanian amyotrophic lateral sclerosis and parkinsonism-dementia patients. J Neurol Sci 1992;109:156-161.
9. Gold M, Hauser RA, Chen MF. Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease. Metab Brain Dis 1998;13:43-53.
10. Kalidass B, Sunnathkal R, Rangashamanna DV, Paraswani R. Atypical Wernicke's encephalopathy showing involvement of substantia nigra. J Neuroimaging 2012;22:204-207.
11. Merkin-Zaborsky H, Ifergane G, Frisher S, Valdman S, Herishanu Y, Wirguin I. Thiamine-responsive acute neurological disorders in nonalcoholic patients. Eur Neurol 2001;45:34-37.
12. Cowen MA, Green M, Bertollo DN, Abbott K. A treatment for tardive dyskinesia and some other extrapyramidal symptoms. J Clin Psychopharmacol 1997;17:190-193.
13. Luong K, Nguyễn L. The beneficial role of Thiamine in Parkinson's disease: preliminary report. J Neurol Res 2012;2:211-214.
14. Luong Kv, Nguyễn LT. Thiamine and Parkinson's disease. J Neurol Sci 2012;316:1-8.
15. Ryu H, Lee J, Zaman K, et al. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci 2003;23:3597-3606.
16. Wang J, Bannon MJ. Sp1 and Sp3 activate transcription of the human dopamine transporter gene. J Neurochem 2005;93:474-482.
17. Yajima S, Lee SH, Minowa T, Mouradian MM. Sp family transcription factors regulate expression of rat D2 dopamine receptor gene. DNA Cell Biol 1998;17:471-479.
18. 1A) receptor gene transcription. Clin Exp Hypertens 1997;19:1-13.
19. 1A dopamine receptor gene. J Biol Chem 1993;268:23544-23551.
20. 2 dopamine receptor gene. J Biol Chem 1994;269:11656-11662.
21. Wong WK, Chen K, Shih JC. Regulation of human monoamine oxidase B gene by Sp1 and Sp3. Mol Pharmacol 2001;59:852-859.
22. Nabokina SM, Said HM. Characterization of the 5′-regulatory region of the human thiamin transporter SLC19A3: in vitro and in vivo studies. Am J Physiol Gastrointest Liver Physiol 2004;287:G822-G829.
23. Nabokina SM, Reidling JC, Said HM. Differentiation-dependent up-regulation of intestinal thiamin uptake: cellular and molecular mechanisms. J Biol Chem 2005;280:32676-32682.
24. Araki N, Morimasa T, Sakai T, et al. Comparative analysis of brain proteins from p53-deficient mice by two-dimensional electrophoresis. Electrophoresis 2002;21:1880-1889.
25. Daily D, Barzilai A, Offen D, Kamsler A, Melamed E, Ziv I. The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53. Cell Mol Neurobiol 1999;19:261-276.
26. Trimmer PA, Smith TS, Jung AB, Bennett JP Jr. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 1996;5:233-239.
27. de la Monte SM, Sohn YK, Ganju N, Wands JR. P53- and CD95-associated apoptosis in neurodegenerative diseases. Lab Invest 1998;78:401-411.
28. Mogi M, Kondo T, Mizuno Y, Nagatsu T. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett 2007;414:94-97.
29. Liang ZQ, Li YL, Zhao XL, et al. NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res 2007;1145:190-203.
30. Biswas SC, Ryu E, Park C, Malagelada C, Greene LA. Puma and p53 play required roles in death evoked in a cellular model of Parkinson disease. Neurochem Res 2005;30:839-845.
31. Zhang C, Lin M, Wu R, et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci USA 2011;108:16259-16264.
32. da Costa CA, Sunyach C, Giaime E, et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 2009;11:1370-1375.
33. Lo PK, Chen JY, Tang PP, et al. Identification of a mouse thiamine transporter gene as a direct transcriptional target for p53. J Biol Chem 2001;276:37186-37193.
34. + modulates p53 DNA binding specificity and function. Mol Cell Biol 2004;24:9958-9967.
35. Yang Z, Ge J, Yin W, Shen H, Liu H, Guo Y. The expression of p53, MDM2 and Ref1 gene in cultured retina neurons of SD rats treated with vitamin B1 and/or elevated pressure. Yan Ke Xue Bao 2004;20:259-263. [Article in Chinese]
36. Sasaki T, Kitagawa K, Yagita Y, et al. Bcl2 enhances survival of newborn neurons in the normal and ischemic hippocampus. J Neurosci Res 2006;84:1187-1196.
37. Jarskog LF, Gilmore JH. Developmental expression of Bcl-2 protein in human cortex. Brain Res Dev Brain Res 2000;119:225-230.
38. Shimohama S, Fujimoto S, Sumida Y, Tanino H. Differential expression of rat brain bcl-2 family proteins in development and aging. Biochem Biophys Res Commun 1998;252:92-96.
39. Zhong LT, Sarafian T, Kane DJ, et al. bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Natl Acad Sci USA 1993;90:4533-4537.
40. Ethell DW, Fei Q. Parkinson-linked genes and toxins that affect neuronal cell death through the Bcl-2 family. Antioxid Redox Signal 2009;11:529-540.
41. Vila M, Jackson-Lewis V, Vukosavic S, et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:2837-2842.
42. Offen D, Beart PM, Cheung NS, et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine neurotoxicity. Proc Natl Acad Sci USA 1998;95:5789-5794.
43. Yamada M, Oligino T, Mata M, Goss JR, Glorioso JC, Fink DJ. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci USA 1999;96:4078-4083.
44. Natsume A, Mata M, Goss J, et al. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration. J Neurotrauma 2002;19:61-68.
45. Seo JH, Rah JC, Choi SH, et al. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J 2002;16:1826-1828.
46. Liu P, Wang X, Gao N, et al. G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression. Brain Res 2010;1307:134-141.
47. Lei Z, Jiang Y, Li T, Zhu J, Zeng S. Signaling of glial cell line-derived neurotrophic factor and its receptor GFRα1 induce Nurr1 and Pitx3 to promote survival of grafted midbrain-derived neural stem cells in a rat model of Parkinson disease. J Neuropathol Exp Neurol 2011;70:736-747.
48. Hayashi T, Justinova Z, Hayashi E, et al. Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats. J Pharmacol Exp Ther 2010;332:1054-1063.
49. Mishina M, Ishiwata K, Ishii K, et al. Function of signal receptors in Parkinson's disease. Acta Neurol Scand 2005;112:103-107.
50. Mori T, Hayashi T, Su TP. Compromising σ-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-κB/Bcl-2-dependent mechanism: potential relevance to Parkinson's disease. J Pharmacol Exp Ther 2012;341:663-671.
51. Rabie T, Mühlhofer W, Bruckner T, et al. Transient protective effect of B-vitamins in experimental epilepsy in the mouse brain. J Mol Neurosci 2010;41:74-79.
52. Ishaque A, Al-Rubeai M. Role of vitamins in determining apoptosis and extent of suppression by bcl-2 during hybridoma cell culture. Apoptosis 2002;7:231-239.
53. Katare R, Caporali A, Emanueli C, Madeddu P. Benfotiamine improves functional recovery of the infarcted heart via activation of pro-survival G6PD/Akt signaling pathway and modulation of neurohormonal response. J Mol Cell Cardiol 2010;49:625-638.
54. Yadav UC, Kalariya NM, Srivastava SK, Ramana KV. Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced cytotoxic signals in murine macrophages. Free Radic Biol Med 2010;48:1423-1434.
55. Beltramo E, Berrone E, Tarallo S, Porta M. Different apoptotic responses of human and bovine pericytes to fluctuating glucose levels and protective role of thiamine. Diabetes Metab Res Rev 2009;25:566-576.
56. Salvesen GS, Riedl SJ. Caspase mechanisms. Adv Exp Med Biol 2008;615:13-23.
57. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 2000;97:2875-2880.
58. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 2000;166:29-43.
59. Burguillos MA, Hajji N, Englund E, et al. Apoptosis-inducing factor mediates dopaminergic cell death in response to LPS-induced inflammatory stimulus: evidence in Parkinson's disease patients. Neurobiol Dis 2011;41:177-188.
60. Dodel RC, Du Y, Bales KR, Ling ZD, Carvey PM, Paul SM. Peptide inhibitors of caspase-3-like proteases attenuate 1-methyl-4-phenylpyridinium-induced toxicity of cultured fetal rat mesencephalic dopamine neurons. Neuroscience 1998;86:701-707.
61. Yamada M, Kida K, Amutuhaire W, Ichinose F, Kaneki M. Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice. Biochem Biophys Res Commun 2010;402:312-318.
62. Liu S, Huang H, Lu X, et al. Down-regulation of thiamine transporter THTR2 gene expression in breast cancer and its association with resistance to apoptosis. Mol Cancer Res 2003;1:665-673.
63. Chornyy S, Parkhomenko J, Chorna N. Thiamine deficiency caused by thiamine antagonists triggers upregulation of apoptosis inducing factor gene expression and leads to caspase 3-mediated apoptosis in neuronally differentiated rat PC-12 cells. Acta Biochim Pol 2007;54:315-322.
64. Gadau S, Emanueli C, Van Linthout S, et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 2006;49:405-420.
65. Kang KD, Majid AS, Kim KA, et al. Sulbutiamine counteracts trophic factor deprivation induced apoptotic cell death in transformed retinal ganglion cells. Neurochem Res 2010;35:1828-1839.
66. Ichinos H, Ohy T, Fujita K, et al. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm 1994;8:149-158.
67. Nakashima A, Ota A, Kaneko YS, Mori K, Nagasaki H, Nagatsu T. A possible pathophysiological role of tyrosine hydroxylase in Parkinson's disease suggested by postmortem brain biochemistry: a contribution for the special 70th birthday symposium in honor of Prof. Peter Riederer. J Neural Transm 2013;120:49-54.
68. Nagatsu T, Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl 2007;113-120.
69. Zhu Y, Zhang J, Zeng Y. Overview of tyrosine hydroxylase in Parkinson's disease. CNS Neurol Disord Drug Targets 2012;11:350-358.
70. Feve AP. Current status of tyrosine hydroxylase in management of Parkinson's disease. CNS Neurol Disord Drug Targets 2012;11:450-455.
71. Korecka JA, Eggers R, Swaab DF, Bossers K, Verhaagen J. Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment. Restor Neurol Neurosci 2013;31:155-167.
72. Aznavour N, Cendres-Bozzi C, Lemoine L, et al. MPTP animal model of Parkinsonism: dopamine cell death or only tyrosine hydroxylase impairment? A study using PET imaging, autoradiography, and immunohistochemistry in the cat. CNS Neurosci Ther 2012;18:934-941.
73. Wang XH, Lu G, Hu X, et al. Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease. BMC Neurosci 2012;13:142.
74. Espadas I, Darmopil S, Vergaño-Vera E, et al. L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function. Neurobiol Dis 2012;48:271-281.
75. Furukawa Y, Graf WD, Wong H, Shimadzu M, Kish SJ. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology 2001;56:260-263.
76. Hertz JM, Ostergaard K, Juncker I, et al. Low frequency of Parkin, tyrosine hydroxylase, and GTP Cyclohydrolase I gene mutations in a Danish population of early-onset Parkinson's disease. Eur J Neurol 2006;13:385-390.
77. Bademci G, Edwards TL, Torres AL, et al. A rare novel deletion of the tyrosine hydroxylase gene in Parkinson disease. Hum Mutat 2010;31:E1767-E1771.
78. Domenger D, Dea D, Theroux L, Moquin L, Gratton A, Poirier J. The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain. Exp Neurol 2012;233:513-522.
79. Nakagawasai O, Yamadera F, Iwasaki K, et al. Preventive effect of kami-untan-to on performance in the forced swimming test in thiamine-deficient mice: relationship to functions of catecholaminergic neurons. Behav Brain Res 2007;177:315-321.
80. Abe Y, Tadano T, Yonezawa A, Kisara K. Suppressive effects of intraventricular injected dopamine and nomifensine on muricide induced by thiamine deficiency. Pharmacol Biochem Behav 1987;26:77-81.
81. Jiang H, Guo W, Liang X, Rao Y. Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators. Cell 2005;120:123-135.
82. Nagao M, Hayashi H. Glycogen synthase kinase-3beta is associated with Parkinson's disease. Neurosci Lett 2009;449:103-107.
83. Hongo H, Kihara T, Kume T, et al. Glycogen synthase kinase-3β activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization. Biochem Biophys Res Commun 2012;426:94-99.
84. Kwok JB, Hallupp M, Loy CT, et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005;58:829-839.
85. Kalinderi K, Fidani L, Katsarou Z, Clarimón J, Bostantjopoulou S, Kotsis A. GSK3β polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort. Neurobiol Aging 2011;32:546.
86. Zhao DM, Li NN, Zhang JH, et al. GSK3β reduces risk of sporadic Parkinson's disease in ethnic Chinese. Am J Med Genet B Neuropsychiatr Genet 2012;159B:718-721.
87. Koh SH, Song C, Noh MY, et al. Inhibition of glycogen synthase kinase-3 reduces L-DOPA-induced neurotoxicity. Toxicology 2008;247:112-118.
88. Zhao J, Sun X, Yu Z, et al. Exposure to pyrimidine increases beta-amyloid accumulation, Tau hyperphosphorylation, and glycogen synthetase kinase-3 activity in the brain. Neurotox Res 2010;19:575-583.
89. Pan X, Gong N, Zhao J, et al. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 2010;133:1342-1351.
90. Yasuhara T, Shingo T, Kobayashi K, et al. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur J Neurosci 2004;19:1494-1504.
91. Falk T, Zhang S, Sherman SJ. Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. Mol Neurodegener 2009;4:49.
92. Barcia C, Bautista V, Sánchez-Bahillo A, et al. Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J Neural Transm 2005;112:1237-1348.
93. Wada K, Arai H, Takanashi M, et al. Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease. NeuroReport 2006;17:705-709.
94. Yasuhara T, Shingo T, Muraoka K, et al. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model. Brain Res 2005;1038:1-10.
95. Nakagawa H, Yoneda M, Maeda A, Umehara F, Kuriyama M. [Thiamine deficiency polyneuropathy after gastrectomy associated with high level of serum vascular endothelial growth factor (VEGF). A case report]. Rinsho Shinkeigaku 2004;44:91-95. Article in Japanese
96. Imai N, Kubota M, Saitou M, Yagi N, Serizawa M, Kobari M. Increase of serum vascular endothelial growth factors in wet beriberi: two case reports. Intern Med 2012;51:929-932.
97. Kihm LP, Müller-Krebs S, Klein J, et al. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol 2011;22:914-926.
98. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005;83:876-886.
99. Kurz A, Rabbani N, Walter M, et al. Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cell Mol Life Sci 2011;68:721-733.
100. Palacino JJ, Sagi D, Goldberg MS, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004;279:18614-18622.
101. Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 1996;737:195-200.
102. Shaikh S, Nicholson LF. Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res 2008;86:2071-2082.
103. Dalfó E, Portero-Otín M, Ayala V, Martínez A, Pamplona R, Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 2005;64:816-830.
104. Teismann P, Sathe K, Bierhaus A, et al. Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol Aging 2012;33:2478-2490.
105. Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley PJ. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia 2010;53:1506-1516.
106. Karachalias N, Babaei-Jadidi R, Kupich C, Ahmed N, Thornalley PJ. High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Ann N Y Acad Sci 2005;1043:777-783.
107. Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006;29:2064-2071.
108. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294-299.
109. Polizzi FC, Andican G, Cetin E, Civelek S, Yumuk V, Burçak G. Increased DNA-Glycation in type 2 diabetic patients: the effect of thiamine and pyridoxine therapy. Exp Clin Endocrinol Diabetes 2012;120:329-334.
110. Hunot S, Brugg B, Ricard D, et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci USA 1997;94:7531-7536.
111. Soós J, Engelhardt JI, Siklós L, Havas L, Majtényi K. The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease. NeuroReport 2004;15:1715-1718.
112. Togo T, Iseki E, Marui W, Akiyama H, Uéda K, Kosaka K. Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. J Neurol Sci 2001;184:71-75.
113. Aoki E, Yano R, Yokoyama H, Kato H, Araki T. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine)-induced apoptosis in nigral neurons of mice. Exp Mol Pathol 2009;86:57-64.
114. Prabhakaran K, Chapman GD, Gunasekar PG. α-Synuclein overexpression enhances manganese-induced neurotoxicity through the NF-κB-mediated pathway. Toxicol Mech Methods 2011;21:435-443.
115. Ghosh A, Roy A, Liu X, et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2007;104:18754-18759.
116. Yadav UC, Subramanyam S, Ramana KV. Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1. Invest Ophthalmol Vis Sci 2009;50:2276-2282.
117. Shoeb M, Ramana KV. Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radic Biol Med 2012;52:182-190.
118. Hipskind RA, Bilbe G. MAP kinase signaling cascades and gene expression in osteoblasts. Front Biosci 1998;3:d804-d816.
119. Zhu JH, Kulich SM, Oury TD, Chu CT. Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am J Pathol 2002;161:2087-2098.
120. Zhu JH, Guo F, Shelburne J, Watkins S, Chu CT. Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Brain Pathol 2003;13:473-481.
121. Kulich SM, Chu CT. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J Neurochem 2001;77:1058-1066.
122. Kulich SM, Horbinski C, Patel M, Chu CT. 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic Biol Med 2007;43:372-383.
123. Dagda RK, Zhu J, Kulich SM, Chu CT. Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. Autophagy 2008;4:770-782.
124. Lynch-Day MA, Mao K, Wang K, Zhao M, Klionsky DJ. The role of autophagy in Parkinson's disease. Cold Spring Harb Perspect Med 2012;2:a009357.
125. Karunakaran S, Ravindranath V. Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-kappaB in MPTP-treated mice: implication in Parkinson's disease. J Neurochem 2009;109:17911-17919.
126. Izumi Y, Yamamoto N, Matsuo T, et al. Vulnerability to glutamate toxicity of dopaminergic neurons is dependent on endogenous dopamine and MAPK activation. J Neurochem 2009;110:745-755.
127. Thomas T, Timmer M, Cesnulevicius K, Hitti E, Kotlyarov A, Gaestel M. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation-relevance in a mouse model of Parkinson's disease. J Neurochem 2008;105:2039-2052.
128. Choi DH, Cristóvão AC, Guhathakurta S, et al. NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxid Redox Signal 2012;16:1033-1045.
129. Kumar A, Singh BK, Ahmad I, et al. Involvement of NADPH oxidase and glutathione in zinc-induced dopaminergic neurodegeneration in rats: similarity with paraquat neurotoxicity. Brain Res 2012;1438:48-64.
130. Zawada WM, Banninger GP, Thornton J, et al. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J Neuroinflammation 2011;8:129.
131. Zhou H, Zhang F, Chen SH, et al. Rotenone activates phagocyte NADPH oxidase by binding to its membrane subunit gp91phox. Free Radic Biol Med 2012;52:303-313.
132. Rodriguez-Pallares J, Rey P, Parga JA, Muñoz A, Guerra MJ, Labandeira-Garcia JL. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis 2008;31:58-73.
133. Cristóvão AC, Choi DH, Baltazar G, Beal MF, Kim YS. The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. Antioxid Redox Signal 2009;11:2105-2118.
134. Anantharam V, Kaul S, Song C, Kanthasamy A, Kanthasamy AG. Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells. Neurotoxicology 2007;28:988-997.
135. Zhang D, Hu X, Wei SJ, et al. Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity. J Neuroinflammation 2008;5:21.
136. Shangari N, Mehta R, O'brien PJ. Hepatocyte susceptibility to glyoxal is dependent on cell thiamin content. Chem Biol Interact 2007;165:146-154.
137. Galdhar NR, Pawar SS. Hepatic drug metabolism and lipid peroxidation in thiamine deficient rats. Int J Vitam Nutr Res 1976;46:14-23.
138. Fraser DA, Hessvik NP, Nikolić N, et al. Benfotiamine increases glucose oxidation and downregulates NADPH oxidase 4 expression in cultured human myotubes exposed to both normal and high glucose concentrations. Genes Nutr 2012;7:459-469.
139. Grosse W 3rd, Wade AE. The effect of thiamine consumption on liver microsomal drug-metabolizing pathways. J Pharmacol Exp Ther 1971;176:758-765.
140. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003;2:107-116.
141. Heetun ZS, Quigley EM. Gastroparesis and Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2012;18:433-440.
142. Davies KN, King D, Billington D, Barrett JA. Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease. Postgrad Med J 1996;72:164-167.
143. Baum RA, Iber FL. Thiamin-the interaction of aging, alcoholism, and malabsorption in various populations. World Rev Nutr Diet 1984;44:85-116.